MAP2K7 and melanoma: Another successful reprofiling example was shown by Fernandez del Ama et al., who, using an oncogenic-RAS-driven zebrafish melanoma model, observed that the mTOR inhibitor rapamycin, as well as the compounds disulfiram and tanshinone, synergized with inhibitors of the MEK and PI3K/mTOR signaling pathways to inhibit melanoma development [202].